ArticleBulletin of experimental biology and medicine2025
Artemisinin Inhibits Drug Resistance and Epithelial-Mesenchymal Transition in Cervical Cancer Cells via the Wnt/β-Catenin Signaling Pathway.
Article in Bulletin of experimental biology and medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The study examined the effects of a plant product artemisinin (ARS) on epithelial-mesenchymal transition and drug resistance in cervical cancer cells mediated via the Wnt/β-catenin signaling pathway. ARS inhibited invasion and migration of CaSki and HeLa cancer cells, up-regulated expression of ICAM-1, MMP-9, and E-cadherin proteins, as well as down-regulated expression of vimentin. In both cell lines, ARS down-regulated mRNA and protein expression of P-glycoprotein, ATP-binding cassette transporters B and G2; it also reduced expression of β-catenin protein. In comparison with the cells treated with Wnt/β-catenin pathway inhibitor iCRT3, the combined treatment of the cells with ARS and iCRT3 reduced their invasion and migration, down-regulated expression of MMP-9, ICAM-1, vimentin, and β-catenin proteins, as well as up-regulated expression of E-cadherin.
Indexed as
Identifiers
41507480What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.